OMADA HEALTH INC Stock Price, News & Analysis

Omada Health (NASDAQ: OMDA) announced a planned nationwide prescribing capability for anti-obesity medications (AOM), including GLP-1s, to integrate medication management into its evidence-based behavior change weight program.

The company reported 53% year-over-year member growth through Q3 2025 and said the prescribing option will be available in all 50 states. Omada cited published analyses showing a 28% greater weight loss at 4 months in its Enhanced GLP-1 Care Track and 0.8% average weight change 12 months after discontinuation in one analysis versus 11–12% gain in trials.

Omada Health (Nasdaq: OMDA) will present two ObesityWeek 2025 posters (Nov 4-5, 2025) reporting real-world evidence that Omada’s behavior-change program may improve outcomes for members on or previously on GLP-1 medications for weight loss.

Key findings: 84% persistence at 24 weeks (n=1,124) with greater weight loss for persistent users (12.1% vs 7.4%), a 54% higher odds of persistence per 10 additional weekly engagements, and an average 0.8% weight change at 12 months post-discontinuation (n=95), with 63.2% maintaining or losing weight.

Omada Health (Nasdaq: OMDA) appointed Thomas Tsang, MD, MPH as Chief Medical Officer on October 27, 2025. Dr. Tsang will lead clinical quality, outcomes, strategy, and innovation across Omada’s multi-condition virtual care platform.

He brings prior roles including founding CEO of Valera Health (raised >$75 million; scaled to >500 employees), CMO at Merck Healthcare Services and Solutions, and policy roles at the Office of the National Coordinator and the U.S. House Ways and Means Committee. Omada highlights its GLP-1 Care Track serving over 100,000 members, recent AI launches OmadaSpark and Meal Map, and a customer base exceeding 2,000 organizations.

Omada Health (Nasdaq: OMDA) will release third quarter 2025 financial results on Thursday, November 6, 2025, after market close. The company will host a conference call to review results at 4:30 PM ET the same day.

A live audio webcast will be available at https://investors.omadahealth.com. A replay will be posted at the same link shortly after the call and will remain accessible for approximately 12 months. Participants can pre-register for the conference call at the provided registration link.

Omada Health (Nasdaq: OMDA) has launched Meal Map, an innovative AI-powered nutrition tool integrated within their Nutritional Intelligence capability. This new feature provides instant feedback on nutrient composition and focuses on nutrient quality rather than calorie counting.

The tool, piloted with over 1,000 members, showed increased meal engagement compared to traditional approaches. Meal Map combines AI-powered feedback with human care teams, offering weekly progress reports on nutritional quality and water intake, along with dietitian-vetted recipes through OmadaSpark.

This evidence-based approach aims to help members improve their relationship with food, particularly relevant in the context of increased GLP-1 medication use and rising fad diet popularity. The focus on nutrient density has been linked to various health benefits, including improved immune system function, energy levels, digestive health, and reduced risk of cardiovascular diseases.

Omada Health (Nasdaq: OMDA) has released groundbreaking analysis challenging common assumptions about weight regain after GLP-1 medication discontinuation. The study of 816 members showed that 63% of participants maintained or continued losing weight 12 months after stopping GLP-1 medications, with only a 0.8% average weight change compared to typical 11-12% weight gain seen in clinical trials.

The analysis tracked outcomes at 6, 9, and 12 months post-discontinuation, demonstrating consistent weight maintenance throughout the year. Omada has supported over 100,000 members taking GLP-1 medications through their GLP-1 Care Track program, which provides behavioral support, dedicated care teams, connected devices, and an AI-enhanced digital experience.

Omada Health (Nasdaq: OMDA) has released groundbreaking research demonstrating significant cost savings from their virtual physical therapy program. The study compared virtual PT to in-person physical therapy for musculoskeletal (MSK) conditions using claims data from July 2019 to May 2023.

Key findings show that Omada's virtual MSK program achieved median per-member-per-month savings exceeding $100 in the first six months, with median gross MSK savings per member over $1,000 at both six and 12 months. The program delivered a positive ROI of 1.8x at both intervals, while reducing total medical care utilization and MSK-related costs compared to traditional in-person therapy.

This research is particularly significant as MSK conditions affect over 50% of U.S. adults and cost the healthcare system more than $420 billion in 2018, surpassing costs for diabetes and heart disease.

Omada Health (Nasdaq: OMDA), a virtual between-visit healthcare provider, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's senior management will engage in a fireside chat on September 9, 2025, at 5:35 pm ET. Investors can access the webcast through the company's investor relations website, with a replay available after the event.

Omada Health (NASDAQ:OMDA), a virtual between-visit healthcare provider, reported strong Q2 2025 financial results with revenue of $61 million, up 49% year-over-year. The company achieved significant member growth of 52% to 752,000 members and improved its financial metrics across the board.

Key financial highlights include gross margin improvement to 66% from 60% in Q2 2024, reduced net loss to $5 million from $11 million, and adjusted EBITDA loss of $0.2 million compared to $6.8 million loss year-over-year. The company maintains a strong cash position of $223 million.

Omada provided FY2025 guidance with revenue expected between $235-241 million and adjusted EBITDA loss of $9-5 million. The company also fully repaid its term loan facility and revolving credit line totaling $31.4 million ahead of schedule.